N6-methyladenosine (m6A) (Synonyms: NSC 29409) |
| Catalog No.GC14698 |
N6-메틸아데노신(m6A)은 모든 고등 진핵생물의 메신저 RNA(mRNA)에 존재하는 가장 일반적인 내부(비캡) 변형입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1867-73-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
N6-methyladenosine (m6A or N6m), an adenosine agonist, of an ED50 value of 17.250 µM [1], is a regulator of adenylate cyclase [2]. As a modification in the messenger RNA (mRNA), it is the most prevalent internal (non-cap) modification of mRNA in all higher eukaryotes. It is involved in the regulation of mRNA stability [3].
Adenylate cyclase catalyzes the formation of cyclic adenosine 3’,5’-monophosphate (cAMP) from ATP [4]. In Calu-6 cells, cAMP increased the stability of human rennin mRNA [5].
Concentration-dependently, N6m prevented the accumulation of hemoglobin and inhibited the initiation of commitment to terminal maturation. Treatment with N6m made cell growth slower, but it did not substantially inhibit DNA synthesis and markedly decrease viability and clonogenic potential of MEL cells. In MEL cells, treatment with N6m resulted in a decrease in the accumulation of βmajor globin mRNA in cytoplasm and affected the structural integrity of this mRNA. The inhibition of commitment induced by N6m was potentiated by adenine, l-homocysteine and/or l-methionine. Adenine, l-homocysteine and l-methionine are involved in the active methylation cycle [6].
In mammals, RNA m6A modification preferentially occurs within the consensus sequence RRACH (R = G or A; H = A, C or U) in 3’ UTRs and gene coding regions. That means m6A plays fundamental roles in the control of RNA processing and translational [7].
References:
[1]. Ribeiro JA and Sebastio AM. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. Br J Pharmacol, 1985, 84(4):911-8.
[2]. Londos C, Wolff J and Cooper DMF. Adenosine as a regulator of adenylate cyclase[M]//Purinergic receptors. Springer Netherlands, 1981:287-323.
[3]. Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature, 2014, 505(7481): 117-120.
[4]. Salomon Y, Londos C and Rodbell M. A highly sensitive adenylate cyclase assay. Analytical biochemistry, 1974, 58(2): 541-548.
[5]. Sinn P L and Sigmund CD. Human renin mRNA stability is increased in response to cAMP in Calu-6 cells. Hypertension, 1999, 33(3): 900-905.
[6]. Vizirianakis IS, Wong W and Tsiftsoglou AS. Analysis of the inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N 6-methyladenosine. Biochemical pharmacology, 1992, 44(5): 927-936.
[7]. Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell research, 2014, 24(12): 1403-1419.
| Cas No. | 1867-73-8 | SDF | |
| Synonyms | NSC 29409 | ||
| Chemical Name | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol | ||
| Canonical SMILES | CNC1=C(N=CN2[C@@]3([H])[C@@](O)([H])[C@@](O)([H])[C@@](O3)([H])CO)C2=NC=N1 | ||
| Formula | C11H15N5O4 | M.Wt | 281.27 |
| Solubility | ≥ 12.2mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5553 mL | 17.7765 mL | 35.553 mL |
| 5 mM | 0.7111 mL | 3.5553 mL | 7.1106 mL |
| 10 mM | 0.3555 mL | 1.7777 mL | 3.5553 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *